Hillstream BioPharma, Inc. (HILS)
Hillstream BioPharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bridgewater, NJ, US. The stock last traded at $0.24, up 5.66% on the session, giving a market capitalisation of $4.2M. On trailing twelve-month figures it carries a trailing P/E of -0.11, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.
Hillstream BioPharma, Inc. is most often compared with the following Healthcare names: